Mirum’s Volixibat Achieves Positive Interim Analyses in VANTAGE PBC and VISTAS PSC Studies
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting children and adults. Mirum has three approved medications: LIVMARLI® (maralixibat) oral solution, CHOLBAM® (cholic acid) capsules, and CHENODAL® (chenodiol) tablets. LIVMARLI, an IBAT inhibitor, is approved for the treatment of two rare liver diseases affecting children and adults. It is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the U.S. (three months and older), in Europe (two months and older), and in other regions globally. It is also approved in the U.S. in cholestatic pruritus in PFIC patients five years of age and older. LIVMARLI has received positive opinion by CHMP in Europe for the treatment of PFIC in patients three months of age and older.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leader in rare liver disease, today announced its participation in The International Liver Congress™ taking place virtually June 23-26, 2021. The company will be presenting an integrated safety analysis of maralixibat in 86 patients with Alagille syndrome (ALGS). Mirum will also be unveiling a multi-national survey of patient reported outcomes data from pregnant women with intrahepatic cholestasis of pregnancy (ICP), conducted in collaboration with ICP Support, a leading patient advocacy group focused on ICP, based in the United Kingdom.
Mike Grey doesn’t have any time to waste. Having regained control of two liver disease drugs from Shire and positioned them for pivotal studies — five years after first handing them off in a deal to sell Lumena, where he was CEO — Grey is steering Mirum straight into an IPO with a $86 million ask.
Mirum Pharmaceuticals Secures $120 Million in Series A Financing to Develop Phase 3-Ready Maralixibat for Rare Liver Diseases
Faced with a steep decline in its own profits in the last quarter, Takeda will have been looking for good numbers from acquisition target Shire – and on the whole the UK-listed firm didn’t disappoint.